U.S. Insulin Market
Severe Uniform U.S. Cost Inflation: Severe Patient and Public Harm
U.S. Insulin Market
- Uniform massive 5-7-fold U.S. insulin price increases in the decade-plus since Medicare Part D began
- Despite severe competition among numerous similar products
- Many insulins on the U.S. market for decades
- Severe U.S. patient and family harm
- Diabetes is the highest spending U.S. brand drug category
- Rising U.S. deaths from unaffordable insulin
- Diabetics traveling to abroad for cheaper black market insulin
Two Key Whistleblower Insulins": Sanofi's Lantus and Eli Lilly's Humulin
Sanofi's Lantus (long-acting insulin, on U.S. market since 2000)
- 2005 Reported U.S. Sales: $846 million
- 2017 Reported U.S. Sales: $4.0 billion
- 2017 U.S. Sales WITHOUT Price Increases: $1.8 billion
- A top-spending drug in Medicare Part D
- Cumulative harm since start of Part D: $21.0+ billion
Eli Lilly’s Humulin (on U.S. market since 1982)
- 2005 Reported U.S. Sales: $411 million
- 2017 Reported U.S. Sales: $885 million
- U.S. Clinical Use/Prescriptions DOWN -60% since 2005
- 2017 U.S. Sales WITHOUT Price Increases: $173 million
- Cumulative harm since start of Part D: $4.1 billion